Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $75.50

AnaptysBio, Inc. (NASDAQ:ANAB) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $76.3636.

Several equities analysts recently issued reports on the company. Wedbush boosted their price objective on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Stifel Nicolaus boosted their price objective on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Piper Sandler boosted their price objective on AnaptysBio from $67.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Leerink Partners boosted their price objective on AnaptysBio from $66.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Truist Financial upgraded AnaptysBio to a “hold” rating in a research note on Wednesday, March 25th.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 17,679 shares of the business’s stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer owned 495,965 shares in the company, valued at approximately $30,556,403.65. The trade was a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric J. Loumeau sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the sale, the insider owned 12,835 shares in the company, valued at $693,090. The trade was a 43.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 48,324 shares of company stock worth $2,787,594. Corporate insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. raised its stake in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter.

AnaptysBio Stock Performance

Shares of ANAB opened at $66.76 on Friday. The stock has a 50 day simple moving average of $60.87 and a 200 day simple moving average of $49.68. AnaptysBio has a 52-week low of $11.40 and a 52-week high of $71.67. The firm has a market capitalization of $1.94 billion, a PE ratio of -128.38 and a beta of 0.79.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The business had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. Equities research analysts predict that AnaptysBio will post -3.15 EPS for the current fiscal year.

AnaptysBio announced that its board has approved a stock buyback plan on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.